tbuckley/cabot-search huggingface dataset:
In situ identification of Gram-negative bacteria in human lungs using a topical fluorescent peptide targeting lipid A
Authors: Ahsan R. Akram, Sunay V. Chankeshwara, Emma Scholefield, Tashfeen Aslam, Neil McDonald, Alicia Megia-Fernandez, Adam Marshall, Bethany Mills, Nicolaos Avlonitis, Thomas H. Craven, Annya M. Smyth, David S. Collie, Calum Gray, Nik Hirani, Adam T. Hill, John R. Govan, Timothy Walsh, Christopher Haslett, Mark Bradley, Kevin Dhaliwal
Journal: Science Translational Medicine (2018)

Respiratory infections in mechanically ventilated patients caused by Gram-negative bacteria are a major cause of morbidity. Rapid and unequivocal determination of the presence, localization, and abundance of bacteria is critical for positive resolution of the infections and could be used for patient stratification and for monitoring treatment efficacy. Here, we developed an in situ approach to visualize Gram-negative bacterial species and cellular infiltrates in distal human lungs in real time. We used optical endomicroscopy to visualize a water-soluble optical imaging probe based on the antimicrobial peptide polymyxin conjugated to an environmentally sensitive fluorophore. The probe was chemically stable and nontoxic and, after in-human intrapulmonary microdosing, enabled the specific detection of Gram-negative bacteria in distal human airways and alveoli within minutes. The results suggest that pulmonary molecular imaging using a topically administered fluorescent probe targeting bacterial lipid A is safe and practical, enabling rapid in situ identification of Gram-negative bacteria in humans.
Response to: ‘“MAINRITSAN2-the future”, with some doubts!’ by Chattopadhyay <i>et al</i>
Authors: Pierre Charles, Loic Guillevin
Journal: Annals of the Rheumatic Diseases (2018)

We would like to thank Chattopadhyay et al 1 for their comments regarding our paper.2 

The MAINtenance of Remission Using RITuximab in Systemic ANCA-associated Vasculitis (MAINRITSAN2) trial was designed in 2011. At that time, the MAINRITSAN trial results were not yet available, which explains why a conservative hypothesis was used to calculate the sample size. Given the low relapse rate (9.9%) observed with rituximab maintenance therapy for antineutrophil cytoplasm antibody (ANCA)-associated vasculitides (AAVs), our study was underpowered to detect an absolute relapse rate difference of 7%. However, a post-hoc power calculation is not necessary to reach this conclusion.3 The individually tailored group had more relapses …
Clinicopathological evaluation of skin lesions (SL) in patients with hepatocellular carcinoma (HCC) treated with sorafenib
Authors: L.G.D. Fonseca, A. Díaz, V. Sapena, Á Díaz-González, L. Boix, M. Sanduzzi-Zamparelli, C. Fuster, N. Llarch, G. Iserte, F. Torres, J. Bruix, M. Reig
Journal: Annals of Oncology (2018)
Fischer rats exhibit maladaptive structural and molecular right ventricular remodelling in severe pulmonary hypertension: a genetically prone model for right heart failure
Authors: Colin M Suen, Ketul R Chaudhary, Yupu Deng, Baohua Jiang, Duncan J Stewart
Journal: Cardiovascular Research (2018)

The ability of the right ventricle (RV) to adapt to increased afterload is the major determinant of survival in patients with pulmonary hypertension (PH). In this study, we explored the effect of genetic background on RV adaptation and survival in a rat model of severe pulmonary arterial hypertension (PAH).PH was induced by a single injection of SU5416 (SU) in age-matched Sprague Dawley (SD) or Fischer rats, followed by a 3-week exposure to chronic hypoxia (SUHx). SD and Fischer rats exhibited similar elevations in RV systolic pressure, number of occlusive pulmonary vascular lesions, and RV hypertrophy (RV/LV+S) in response to SUHx. However, no Fischer rats survived beyond 7 weeks compared with complete survival for SD rats. This high early mortality of Fischer rats was associated with significantly greater RV dilatation and reduced ejection fraction, cardiac output, and exercise capacity at 4 weeks post-SU. Moreover, microarray analysis revealed that over 300 genes were uniquely regulated in the RV in the severe PAH model in the Fischer compared with SD rats, mainly related to angiogenesis and vascular homoeostasis, fatty acid metabolism, and innate immunity. A focused polymerase chain reaction array confirmed down-regulation of angiogenic genes in the Fischer compared with SD RV. Furthermore, Fischer rats demonstrated significantly lower RV capillary density compared with SD rats in response to SUHx.Fischer rats are prone to develop RV failure in response to increased afterload. Moreover, the high mortality in the SUHx model of severe PAH was caused by a failure of RV adaptation associated with lack of adequate microvascular angiogenesis, together with metabolic and immunological responses in the hypertrophied RV.
Serum markers as predictors of immune checkpoint inhibitors (ICI) related adverse events in a real-world scenario
Authors: D. Iacono, M.G. Vitale, F. Cortiula, M. Cinausero, A. Tullio, F. Valent, M. Macerelli, A. Follador, A. Vogrig, A.M. Minisini, F. Puglisi, G. Fasola
Journal: Annals of Oncology (2018)
Abstract 18662: Oral Calpain Inhibition Attenuates Inflammation,Hypertrophy and Fibrosis in Distant Myocardium After Transient Coronary Occlusion
Authors: Javier Inserte, Marcos Poncelas, David Aluja, Ursula Vilardosa, Laura Ramos, David Garcia-Dorado
Journal: Circulation (2016)

Background: Post-infarction remodeling is an important cause of heart failure and a major medical and social problem. Calpains have been associated with inflammatory responses. Objective: To determ...
Practice patterns and deterioration of liver function after transarterial chemoembolization (TACE) in hepatocellular carcinoma (HCC): Final analysis of OPTIMIS in Europe and Canada
Authors: J.-L. Raoul, T. Decaens, K. Burak, J. Koskinas, G.E. Villadsen, A. Heurgue-Berlot, I. Bayh, A.-L. Cheng, M. Kudo, H.C. Lee, K. Nakajima, M. Peck-Radosavljevic
Journal: Annals of Oncology (2018)
Derived neutrophil-to lymphocyte ratio (dNLR) change between baseline and cycle 2 is correlated with benefit during immune checkpoint inhibitors (ICI) in advanced non-small cell lung cancer (NSCLC) patients
Authors: L. Mezquita, K. Arbour, E. Auclin, D. Saravia, H. Rizvi, L. Hendriks, D. Planchard, W. Park, E. Nadal, J.C. Ruffinelli Rodriguez, S. Ponce, C. Audigier-Valette, A.P. Marilniello, G. Zalcman, M. Majem, G. Schiavone, A.-M.C. Dingemans, G. Lopes, M.D. Hellmann, B. Besse
Journal: Annals of Oncology (2018)
P1.05-19 CT and PET/CT Parameters of Lepidic Predominant Pattern Lung Adenocarcinoma and Invasiveness on Pathology
Authors: H. Takizawa, M. Takashima, D. Matsumoto, N. Kawakita, T. Sawada, M. Tsuboi, H. Toba, M. Yoshida, Y. Kawakami, K. Kondo, A. Tangoku
Journal: Journal of Thoracic Oncology (2018)
Clinical significance of RCAS1 and CD3 expression in non-small cell lung cancers in immunotherapy era
Authors: N.G. Tsoukalas, E. Aravantinou, K. Tsapakidis, C. Giaginis, M. Tolia, I. Binas, P. Baxevanos, M. Galanopoulos, M. Kiakou, I. Kostakis, C. Nikolaou, I. Litos, M. Liontos, E. Tsiambas, I. Gioulbasanis, I. Sfiniadakis, A. Karameris, G. Kyrgias, S. Theocharis, M. Tsiatas
Journal: Annals of Oncology (2018)
P3.08-18 Changing Resistance Mechanisms in Rebiopsies of ALK-Positive NSCLC During Multiple Lines of Therapy: ALK/BRAF-Mutations Followed By EMT
Authors: E. Urbanska, L. Melchior, K. De Stricker, J.B. Sørensen, E. Santoni Rugiu
Journal: Journal of Thoracic Oncology (2018)
Patient-reported outcomes (PROs) in advanced breast cancer (ABC) treated with ribociclib + fulvestrant: Results from MONALEESA-3
Authors: P.A. Fasching, F.J. Esteva, X. Pivot, A. Nusch, J.T. Beck, A. Chan, A. Pieris-Gunatilaka, Y. Wang, B. Lanoue, D. Chandiwana, P. Neven
Journal: Annals of Oncology (2018)
PINES: phenotype-informed tissue weighting improves prediction of pathogenic noncoding variants
Authors: Corneliu A. Bodea, Adele A. Mitchell, Alex Bloemendal, Aaron G. Day-Williams, Heiko Runz, Shamil R. Sunyaev
Journal: Genome biology (2018)

Functional characterization of the noncoding genome is essential for biological understanding of gene regulation and disease. Here, we introduce the computational framework PINES (Phenotype-Informed Noncoding Element Scoring), which predicts the functional impact of noncoding variants by integrating epigenetic annotations in a phenotype-dependent manner. PINES enables analyses to be customized towards genomic annotations from cell types of the highest relevance given the phenotype of interest. We illustrate that PINES identifies functional noncoding variation more accurately than methods that do not use phenotype-weighted knowledge, while at the same time being flexible and easy to use via a dedicated web portal.
Role of FGFR2 amplification in prognosis of patients with ovarian cancer
Authors: A. Tyulyandina, I. Demidova, M. Gikalo, S. Tjulandin, I. Tsimafeyeu
Journal: Annals of Oncology (2018)

Background: Fibroblast growth factor receptor (FGFR) signaling has been implicated to play a role in tumorigenesis. Aim of this study was to evaluate rate of FGFR2 amplification and preliminary role in patients (pts) with ovarian cancer (OC). Methods: Material from each patient with advanced OC included 3 paraffin-embedded samples: primary ovarian tumor, primary metastatic lesion, and relapse lesion. Samples were analyzed by fluorescence in situ hybridization (FISH) to identify FGFR2 amplification and level of polysomy. Scoring for amplification and polysomy level was adopted from previous studies for gastric cancer [Su et al. BJC 2014]. The analysis was performed in all three samples regardless of the presence of FGFR2 amplification or heterogeneity in primary tumor. Results: 166 samples from 67 pts with advanced ovarian cancer (OC) stage Ic-IV were analysed. Amplification was detected in 11 of 67 pts (16.4%) and high-level polysomy in 31 of 67 (46.3%). All three tumour samples were analyzed in 43 pts. FGFR2 amplification, high-level polysomy were detected in 9 (20.9%) and 19 (44.2%), respectively. Analysis of survival differences revealed no statistically significant difference between the pts with polysomy and non-amplified pts (HR 2.12; 95% CI 0.17-0.21, p = 0.32). Median progressive free survival (PFS) after first line platinum based chemotherapy was 12.6 months in pts with amplification in comparison with 23.1 months in non-amplified (p = 0,012). Pts with amplification in primary tumour (ovary) had statistically poor prognosis than non-amplified pts: median PFS was 12.0 and 22.6 months respectively (p = 0.003). Pts with FGFR2 amplification in primary metastatic lesions and relapsed tumour had tendency to poor prognosis: PFS was 10.3 and 19.6 months in primary metastasis lesions (p = 0.09), and 10.3 vs 22.6 months in relapsed lesions (p = 0.07). Conclusions: We described FGFR2 amplification in 16.4% of pts with advanced OC. Preliminary data demonstrate a negative impact of the FGFR2 amplification in primary tumour (ovary) on long-term outcomes. Legal entity responsible for the study: Alexandra Tyulyandina. Funding: Has not received any funding. Disclosure: All authors have declared no conflicts of interest.
Intrinsic and extrinsic regulation of PD-L2 expression by transcription factor STAT3 or c-FOS in oncogene-driven non-small cell lung cancer
Authors: D. Shibahara, K. Tanaka, E. Iwama, N. Kubo, K. Ota, K. Azuma, T. Harada, J. Fujita, Y. Nakanishi, I. Okamoto
Journal: Annals of Oncology (2018)
ACE inhibitors are linked to increased lung cancer risk, study finds
Authors: Zosia Kmietowicz
Journal: BMJ (2018)

Angiotensin converting enzyme inhibitors (ACEIs) are associated with a higher risk of lung cancer than angiotensin receptor blockers (ARBs), especially if used for more than five years, a study in The BMJ has found.1

Although the risk to individual patients is modest, the absolute numbers of patients at risk for lung cancer is potentially large because ACEIs are widely prescribed, said the researchers.

Evidence suggests that ACEIs increase the risk of lung cancer through the build-up of bradykinin and substance P …
TCR beta chain convergence defines the tumor infiltrating T cell repertoire of melanoma and non-small cell lung carcinoma
Authors: T. Looney, G. Lowman, L. Miller, E. Linch
Journal: Annals of Oncology (2018)

Background: T cell convergence refers to the process whereby antigen-driven selection enriches for T cell receptors having a shared antigen specificity but different amino acid or nucleotide sequence. T cell recruitment and expansion within the tumor microenvironment (TME) may be directed by responses to tumor neoantigen, suggesting that elevated T cell convergence could be a general feature of the tumor infiltrating T cell repertoire. Here we evaluate evidence for T cell convergence in tumor biopsy from research subjects with melanoma and non-small cell lung carcinoma (NSCLC) and peripheral blood leukocytes (PBL) from healthy donors. Methods: Total RNA from 63 melanoma and 19 NSCLC tumor biopsy research samples (non-FFPE) was extracted for use in long-amplicon TCRB chain sequencing (mean amplicon of 330bp covering CDR1, 2 and 3) via the Oncomine TCR Beta-LR Research Assay. To evaluate T cell convergence, we searched for instances where TCRB chains were identical in amino acid space but had distinct nucleotide sequences owing to N-addition and exonucleotide chewback within the V-D and D-J junctions of the CDR3. To provide context, we evaluated evidence for T cell convergence in PBL T cell repertoires derived from 16 healthy donors. Results: Sequencing of melanoma biopsy research samples typically yielded within the range of 2000 to 8000 clones per sample. Convergent T cell receptors were identified in the great majority of melanoma and NSCLC tumor infiltrating T cell repertoires having greater than 100 detected clones (92% and 100%, respectively). The frequency of convergent T cell rearrangements was significantly greater in melanoma and NSCLC tumor biopsies than T cell repertoires derived from healthy PBL research samples. Conclusions: These data suggest that T cell convergence may be a common feature of the melanoma and NSCLC infiltrating T cell repertoire. Convergence was more frequently observed within the TME than T cell repertoires derived from healthy PBL, consistent with elevated antigen-driven T cell selection within the TME. The finding of elevated T cell convergence in melanoma and NSCLC suggests that convergence may be a hallmark of immunogenic tumors. For research use only. Legal entity responsible for the study: Thermo Fisher Scientific. Funding: Thermo Fisher Scientific. Disclosure: T. Looney, G. Lowman, L. Miller, E. Linch: Employee: Thermo Fisher Scientific.
Progastrin, a new blood biomarker for the diagnostic and therapeutic monitoring, in gastro-intestinal cancers: A BIG-RENAPE project
Authors: B. You, V. Kepenekian, A. Prieur, M. Caceres, L.F. Payen-Gay, P. Liaud, M. Flaceliere, M. Tod, L. Villeneuve, F. Bibeau, L. Bernard, P. Jourdan-Enfer, N. Medeghri, D. Dayde, S. Calattini, G. Freyer, D. Maucort-Boulch, D. Joubert, O. Glehen
Journal: Annals of Oncology (2018)
Survival-associated factors and a prognostic nomogram in resected pancreatic cancer: A large international population-based cohort study
Authors: L. Huang, Y. Balavarca, L. van der Geest, V. Lemmens, L. van Eycken, H. De Schutter, T.B. Johannesen, V. Zadnik, M. Primic-Žakelj, M. Mägi, R. Grützmann, M.G. Besselink, P. Schrotz-King, H. Brenner, L. Jansen
Journal: Annals of Oncology (2018)
P2.16-33 Adenosquamous Carcinoma of the Lung: Comparison of Surgical Outcomes with Squamous Cell and Adenocarcinoma
Authors: H. Melek, G. Çetinkaya, A.S. Bayram, E.U. Akyildiz, E. Yenturk, E. Ozer, T. Sevinç, C. Gebitekin
Journal: Journal of Thoracic Oncology (2018)
Analysis of circulating biomarkers in a randomized phase II trial of maintenance oral metronomic vinorelbine in advanced NSCLC following platinum-based chemotherapy: A correlative MA.NI.LA. trial study
Authors: M. Boeri, F. Nichetti, L. Porcu, V. Torri, A. Del Conte, A. Martinetti, E. Sottotetti, E. Vattemi, F. Verderame, M.C. Garassino, L. Cavanna, A. Tuzi, L. Irtelli, F.G.M. de Braud, M. Platania
Journal: Annals of Oncology (2018)
P1.01-99 Detecting HER2 Alterations by Next Generation Sequencing (NGS) in Patients with Advanced NSCLC from the United States and China
Authors: C. Xu, Y. Zhang, D. Liu, R. Shen, P. Razavi, S. Liu, H. Sun, M. Offin, A. Drilon, C. Rudin, M. Arcila, Y. Wu, B. Li
Journal: Journal of Thoracic Oncology (2018)
An oral dual inhibitor of IDO and TDO enhances anti-cancer immunity and synergizes with immune checkpoint blockade
Authors: C. Kim, N.K. Lee, J.S. Kim, W.R. Kim, D.H. Kim, D.J. Kim, J.S. Oh, S.K. Chang, J.W. Kim, H.J. Chon
Journal: Annals of Oncology (2018)
P2.12-19 Prophylactic Cranial Irradiation in Extensive Small Cell Lung Cancer: A Meta-Analysis of Randomized Controlled Trials
Authors: W. Li, T. Zhao, H. Xu, Z. Wang, Y. Xu, Y. Song, J. Wu, H. Xu, S. Yin, X. Liu, Z. Miao
Journal: Journal of Thoracic Oncology (2018)
Short-course regimens of rifapentine plus isoniazid to treat latent tuberculosis infection in older Chinese patients: a randomised controlled study
Authors: Lei Gao, Haoran Zhang, Henan Xin, Jianmin Liu, Shouguo Pan, Xiangwei Li, Ling Guan, Fei Shen, Zisen Liu, Dakuan Wang, Xueling Guan, Jiaoxia Yan, Hengjing Li, Boxuan Feng, Xuefang Cao, Yu Chen, Wei Cui, Zongde Zhang, Yu Ma, Xiaoyou Chen, Xinhua Zhou, Qi Jin
Journal: European Respiratory Journal (2018)

Latent tuberculosis infection (LTBI) management is now a critical component of the World Health Organization's End TB Strategy.In this randomised controlled trial (Chinese Clinical Trial Registry identifier ChiCTR-IOR-15007202), two short-course regimens with rifapentine plus isoniazid (a 3-month once-weekly regimen and a 2-month twice-weekly regimen) were initially designed to be evaluated for rural residents aged 50-69 years with LTBI in China.Due to the increasingly rapid growth and unexpected high frequency of adverse effects, the treatments were terminated early (after 8 weeks for the once-weekly regimen and after 6 weeks for the twice-weekly regimen). In the modified intention-to-treat analysis on the completed doses, the cumulative rate of active disease during 2 years of follow-up was 1.21% (14 out of 1155) in the untreated controls, 0.78% (10 out of 1284) in the group that received the 8-week once-weekly regimen and 0.46% (six out of 1299) in the group that received the 6-week twice-weekly regimen. The risk of active disease was decreased, with an adjusted hazard ratio of 0.63 (95% CI 0.27-1.43) and 0.41 (95% CI 0.15-1.09) for the treatments, respectively. No significant difference was found in the occurrence of hepatotoxicity (1.02% (13 out of 1279) versus 1.17% (15 out of 1279); p=0.704).The short regimens tested must be used with caution among the elderly because of the high rates of adverse effects. Further work is necessary to test the ultrashort regimens in younger people with LTBI.
P2.09-13 Correlation of ROS1 (SP384) Immunohistochemistry with ROS1 Rearrangement Determined by Fluorescence in Situ Hybridization
Authors: R. Huang, D. Smith, B. Richardson, C. Le, W. Liu, A. Hanlon Newell, G. Pate, I. Menzl
Journal: Journal of Thoracic Oncology (2018)
Effects of abiraterone acetate plus prednisone/prednisolone in high and low risk metastatic hormone sensitive prostate cancer
Authors: A.P. Hoyle, S.A. Ali, N.D. James, C.C. Parker, A.D. Cook, G. Attard, S. Chowdhury, W. Cross, D.P. Dearnaley, J.S. de Bono, C.E. Gilson, S. Gillessen, R. Jones, D. Matheson, M.D. Mason, A. Ritchie, M. Russell, M.K. Parmar, M.R. Sydes, N.W. Clarke
Journal: Annals of Oncology (2018)
MA08.09 Impact of Brain Metastases in Immune Checkpoint Inhibitors (ICI) Treated Advanced Non-Small Cell Lung Cancer (NSCLC) Patients
Authors: L. Hendriks, C. Henon, E. Auclin, L. Mezquita, R. Ferrara, C. Audigier-Valette, J. Mazieres, C. Lefebvre, S. Le Moulec, S. Cousin, B. Duchemann, C. Le Pechoux, A. Botticella, S. Ammari, A. Gazzah, C. Caramella, J. Adam, D. Planchard, D. De Ruysscher, A. Dingemans, B. Besse
Journal: Journal of Thoracic Oncology (2018)
P3.04-10 Monocytes and Neutrophils as Predictive Markers of Response to Immune Checkpoint Inhibitors in Metastatic Non-Small Cell Lung Cancer
Authors: K. Parikh, A. Kumar, J. Ahmed, A. Anwar, C. Puccio, H. Chun, M. Fanucchi, S. Lim
Journal: Journal of Thoracic Oncology (2018)
Phase I/II study of single agent MCLA-128, a full length IgG1 bispecific antibody targeting the HER3 pathway: Overall safety at the recommended phase II dose (R2PD) and preliminary activity in HER2+ metastatic gastric/gastroesophageal junction cancer (GC/GEJ)
Authors: M. Alsina, A. Varga, A. Amatu, J.H.M. Schellens, P.O. Witteveen, V. Boni, V. Moreno, K. Bol, A. Lourbakos, M. Magin Ferrer, E. Wasserman
Journal: Annals of Oncology (2018)
The GATTO study: A phase I of the anti-EGFR tomuzotuximab (TO) in combination with the anti-MUC1 gatipotuzumab (GAT) in patients with EGFR positive solid tumors
Authors: E. Garralda, M. van Hoef, S. Ochsenreither, L. Gianni, D. Lorusso, W. Fiedler, U. Keilholz, K. Klinghammer, C. Dicke, M. Kebenko, I. Matos, J. Tabernero, F. Raspagliesi, G. Del Conte, B. Habel, H. Baumeister, A. Zurlo
Journal: Annals of Oncology (2018)
Neoadjuvant biomarker research study of palbociclib combined with endocrine therapy in estrogen receptor positive/HER2 negative breast cancer: The phase II NeoRHEA trial
Authors: M. Ignatiadis, M. Brandao, M. Maetens, N. Ponde, S. Martel, S. Drisis, I. Veys, S. Mazy, E. Bollue, P. Neven, F.P. Duhoux, J. Chapiro, A.H. Awada, T. Besse-Hammer, M. Paesmans, M. Piccart, P. Vuylsteke, C. Sotiriou
Journal: Annals of Oncology (2018)
P1.14-09 Outcome After Lung Resection for Primary Lung Carcinomas/Metastasis in Patients with Performed Total Laryngectomy for Laryngeal Carcinoma
Authors: G. Çetinkaya, N. Çıtak, B. Özkan, H. Melek, F. Amirov, F.N. Kaya, Z. Sungur, Y. Aksoy, A.S. Bayram, A. Toker, A. Sayar, C. Gebitekin
Journal: Journal of Thoracic Oncology (2018)
P1.01-18 Immunosenescence Correlates with Progression upon PD-(L)-1 Blockade (IO) in Advanced Non-Small Cell Lung Cancer (aNSCLC) Patients
Authors: R. Ferrara, M. Naigeon, E. Auclin, B. Duchemann, L. Cassard, J. Medhi, L. Boselli, J. Grivel, A. Desnoyer, L. Mezquita, F. Aboubakar Nana, L. Hendriks, D. Planchard, C. Caramella, J. Remon, M. Ngocamus, C. Nicotra, B. Besse, N. Chaput
Journal: Journal of Thoracic Oncology (2018)
Impact of the multidisciplinary approach on the survival of squamous head and neck cancer in our institution
Authors: M.J. Martínez-Ortiz, Á Martínez-Ortiz, G. Marín-Zafra, P. Cerezuela-Fuentes, J. Balsalobre, J.A. Díaz-Manzano, J. Trujillo-Santos, M.T. García-García
Journal: Annals of Oncology (2018)
Biomarker-driven access to crizotinib in ALK, MET or ROS1 positive (+) malignancies in adults and children: The French national AcSé program
Authors: G. Vassal, N. Cozic, R. Houot, L. Brugières, T. Aparicio, J.-Y. Blay, M. Perol, P. Brice, E. Meriaux, B. Geoerger, M.R. El Bejjani, S. Moalla, I. Bièche, S. Lantuejoul, C. Mahier Ait Oukhatar, N. Hoog Labouret, D. Moro-Sibilot
Journal: Annals of Oncology (2018)
Levels of circulating fibroblast growth factor (FGF) 23 and prognosis of cancer patients with bone metastasis
Authors: A.B. Mansinho, A.R. Ferreira, S. Casimiro, I. Alho, I. Vendrell, A.L. Costa, R.T.D. Sousa, C.D. Abreu, C. Pulido, D. Macedo, T. Pacheco, L. Correia, L. Costa
Journal: Annals of Oncology (2018)
Cabozantinib in patients with advanced osteosarcomas and Ewing sarcomas: A French Sarcoma Group (FSG)/ US National Cancer Institute phase II collaborative study
Authors: A. Italiano, N. Penel, M. Toulmonde, E. Bompas, S. Piperno-Neumann, M. Pulido, N. Entz-Werle, A. Le Cesne, C.M. Chevreau, F. Duffaud, I.L. Ray-Coquard, C. Bellera, S. Mathoulin-Pelissier, J.-Y. Blay
Journal: Annals of Oncology (2018)
MA22.09 Should Stereotactic Radiosurgery be Considered for Salvage of Intracranial Recurrence in Small Cell Lung Cancer?
Authors: B. Mazure, N. Guest, A. Letcher, S. Ghosh, Z. Gabos, K. Chu, B. Debenham, T. Nijjar, D. Severin, R. Scrimger, W. Roa, D. Yee, A. Fairchild
Journal: Journal of Thoracic Oncology (2018)